A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

Inclusion Criteria:

• Men and women ≥18 and ≤75 years old on the day of signing the ICF

• At least 1 measurable lesion per RECIST v1.1

• Expected survival ≥3 months

• ECOG PS score of 0 or 1

• Adequate organ function

• Female participants of childbearing potential or male participants whose partner isa female of childbearing potential agree to use medically effective contraceptivemethods (abstinence, birth control pills, barrier contraception, intra-uterinecontraceptive device, etc.) from the date of signing the ICF until at least 6 monthsafter the last dose of ALK202, and during this period, male participants are notallowed to donate sperms.

Exclusion Criteria:

• Received organ transplant or hematopoietic stem cell transplant previously

• Vaccinated with live vaccines within 4 weeks prior to the first dose

• Primary central nervous system malignancies, or active metastases to central nervoussystem and/or metastases to meninges

• Pregnant or lactating women

• Pleural effusion, pericardial effusion, or intraperitoneal effusion accompanied withclinical symptoms, clinically poorly controlled, or requiring repeated drainage.

• Evidence of other severe or uncontrolled systemic diseases (e.g., decompensatedrespiratory disorder, hepatic disease, or renal disease).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.